BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18258382)

  • 1. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
    van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial.
    Hoffmann AL; Troost EG; Huizenga H; Kaanders JH; Bussink J
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1596-602. PubMed ID: 22245206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.
    Marnitz S; Stuschke M; Bohsung J; Moys A; Reng I; Wurm R; Budach V
    Strahlenther Onkol; 2002 Nov; 178(11):651-8. PubMed ID: 12426677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
    Dirkx ML; van Sörnsen De Koste JR; Senan S
    Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced head and neck carcinoma in women: treatment outcomes may not improve with accelerated hyperfractionated radiotherapy.
    Leborgne F; Leborgne JH; Fowler JF; Zubizarreta E; Mezzera J
    Cancer; 2001 Jun; 91(12):2353-60. PubMed ID: 11413525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients.
    St-Hilaire J; Sévigny C; Beaulieu F; Germain F; Lavoie C; Dagnault A; Gingras L; Tremblay D; Beaulieu L
    Radiother Oncol; 2009 Jun; 91(3):342-8. PubMed ID: 19135749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tumor repopulation on radiotherapy planning.
    Wang JZ; Li XA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer.
    van Baardwijk A; Wanders S; Boersma L; Borger J; Ollers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Lunde R; Lambin P; De Ruysscher D
    J Clin Oncol; 2010 Mar; 28(8):1380-6. PubMed ID: 20142596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
    Pemberton LS; Din OS; Fisher PM; Hatton MQ
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
    Chang JY; Zhang X; Wang X; Kang Y; Riley B; Bilton S; Mohan R; Komaki R; Cox JD
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1087-96. PubMed ID: 16682145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.
    Onimaru R; Fujino M; Yamazaki K; Onodera Y; Taguchi H; Katoh N; Hommura F; Oizumi S; Nishimura M; Shirato H
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):374-81. PubMed ID: 18029106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two dimensional and three dimensional radiotherapy treatment planning in locally advanced non-small cell lung cancer treated with continuous hyperfractionated accelerated radiotherapy weekend less.
    Wilson EM; Joy Williams F; Lyn BE; Aird EG
    Radiother Oncol; 2005 Mar; 74(3):307-14. PubMed ID: 15763312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of microscopic disease on the tumor control probability in non-small-cell lung cancer.
    Siedschlag C; Boersma L; van Loon J; Rossi M; van Baardwijk A; Gilhuijs K; Stroom J
    Radiother Oncol; 2011 Sep; 100(3):344-50. PubMed ID: 21955665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer--report on clinical outcome and dose to critical organs.
    Ng AW; Tung SY; Wong VY
    Radiother Oncol; 2008 Apr; 87(1):24-8. PubMed ID: 18334273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of forward planning with automated inverse planning for three-dimensional conformal radiotherapy of non-small cell lung cancer without IMRT.
    Mendes R; Lavrenkov K; Bedford JL; Henrys A; Ashley S; Brada M
    Radiother Oncol; 2006 Mar; 78(3):322-5. PubMed ID: 16564591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.